Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib with or without Bevacizumab in GIST
NCT00324987Phase 3Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2008
- Primary completion
- Jul 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of bevacizumab in gastrointestinal stromal tumor (GIST), sponsored by National Cancer Institute. Started Apr 2008; status: terminated.
02
Drugs
bevacizumab
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00324987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00324987.